ClearArc Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

ClearArc Capital’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-27,894	Closed	-$969K	–	466
2015 Q2	$969K	Sell	27,894 -153	-0.5%	-$4.67K	0.18%	154
2015 Q1	$728K	Buy	+28,047	New	+$514K	0.15%	178

Other funds holding HZNP

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $16.4B AUM 99.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

ClearArc Capital's HZNP Position: Q3 2015 in Review

ClearArc Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2015, closing a stake of 27,894 shares — an estimated $969K sold.

ClearArc Capital first reported a position in HZNP in Q1 2015 and held it in 2 quarters. The position peaked at $969K in Q2 2015. 223 funds tracked by Wall St. Rank hold HZNP as of Q3 2015.

ClearArc Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2015 after selling out during the quarter.
ClearArc Capital sold 27,894 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2015, an estimated $969K.
ClearArc Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2015 and held it in 2 quarters.
ClearArc Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $969K in Q2 2015.
223 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2015.

Based on ClearArc Capital's 13F filing for Q3 2015, filed 13 Nov 2015.